Visualant Enters $10 Million Qualcomm Tricorder XPRIZE

Visualant Enters $10 Million Qualcomm Tricorder XPRIZE

Competition to leverage technology innovation in areas such as artificial
intelligence and wireless sensing

SEATTLE, Wash., June 10, 2013 (GLOBE NEWSWIRE) -- via PRWEB - Visualant, Inc.
(OTCBB:VSUL) – an industry-leading provider of chromatic-based identification
and diagnostic solutions with its ChromaID™ technology, announced today it is
entering into the Qualcomm Tricorder XPRIZE, a global competition to
revolutionize healthcare. In this competition, teams will leverage technology
innovation in areas such as artificial intelligence and wireless sensing –
much like the medical Tricorder of Star Trek® fame – to make medical diagnoses
independent of a physician or healthcare provider. The goal of the competition
is to drive development of devices that will give consumers access to their
state of health in the palm of their hand.

Professor Tom Furness (Chairman of the Visualant's Scientific Advisory Board)
is leading a team of students and researchers applying Visualant's ChromaID
technology to health sensing opportunities. Professor Furness has considerable
experience in the development of sensing technologies, having received the
2001 Satava Award (with the University of Washington HIT Lab) for advances in
medical technology and in 1998 the Discover Award for Technological Innovation
for his ground-breaking Virtual Retinal Display technology.

"The Qualcomm Tricorder XPRIZE provides a great catalyst for our research team
to apply our ChromaID technology to enhance mobile healthcare devices", said
Ron Erickson, President and CEO of Visualant. "We are also excited about the
potential to collaborate with other teams through the framework provided by
the XPRIZE organization."

The Qualcomm Tricorder XPRIZE is a $10 million global competition to stimulate
innovation and integration of precision diagnostic technologies, making
reliable health diagnoses available directly to "health consumers" in their

For more information about team Visualant, please visit

About Visualant, Inc.

Visualant™ is a public company whose shares trade under the stock symbol,
VSUL. The Visualant Spectral Pattern Matching™ technology directs structured
light onto a substance, through a liquid/gas, or off a surface, to capture a
unique ChromaID™. When matched against existing databases, a ChromaID can be
used to identify, detect, or diagnosis markers invisible to the human eye.
ChromaID scanner modules can be integrated into a variety of mobile or
fixed-mount form factors. The patented technology is disruptive, making it
possible to effectively conduct analyses in the field that could only
previously be performed by large and expensive lab–based tests.

Visualant entered into a one year Joint Development Agreement on May 31, 2012
with Sumitomo Precision Products Co., Ltd. ("SPP"), which focuses on the
commercialization of the SPM technology and a License Agreement providing SPP
with an exclusive license of the SPM technology in identified Asian
territories. For more information, visit

Sumitomo Precision Products Co., Ltd. Is publicly traded and has operations in
Japan, United States, China, United Kingdom, Canada, and other parts of the
world. Additional information on SPP is available at

Press contacts:

Hal Bringman
+1 (206) 299-0622 ext 801
+1 (310) 210-8011
Skype halbringman

Tina Qunell
+1 (206) 919-9652

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit

         Hal Bringman
         (323) 851-6877
Press spacebar to pause and continue. Press esc to stop.